1. Home
  2. KLTR vs ABOS Comparison

KLTR vs ABOS Comparison

Compare KLTR & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kaltura Inc.

KLTR

Kaltura Inc.

HOLD

Current Price

$1.60

Market Cap

218.0M

Sector

Technology

ML Signal

HOLD

Logo Acumen Pharmaceuticals Inc.

ABOS

Acumen Pharmaceuticals Inc.

HOLD

Current Price

$3.03

Market Cap

197.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KLTR
ABOS
Founded
2006
1996
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
218.0M
197.9M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
KLTR
ABOS
Price
$1.60
$3.03
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$3.00
$8.00
AVG Volume (30 Days)
1.1M
349.7K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
61.90
N/A
EPS
N/A
N/A
Revenue
$180,854,000.00
N/A
Revenue This Year
$2.96
N/A
Revenue Next Year
$4.96
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.20
N/A
52 Week Low
$1.06
$1.21
52 Week High
$2.05
$3.60

Technical Indicators

Market Signals
Indicator
KLTR
ABOS
Relative Strength Index (RSI) 52.51 68.57
Support Level $1.56 $2.13
Resistance Level $1.68 $3.60
Average True Range (ATR) 0.08 0.18
MACD -0.02 0.05
Stochastic Oscillator 38.02 74.23

Price Performance

Historical Comparison
KLTR
ABOS

About KLTR Kaltura Inc.

Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.

About ABOS Acumen Pharmaceuticals Inc.

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Share on Social Networks: